Antivirals, Antimalarials, and Anthelmintics



Antivirals, Antimalarials, and Anthelmintics


Objectives



Key Terms


acquired immunodeficiency syndrome, p. 450


anthelmintics, p. 457


antimalarial drugs, p. 454


antiviral drugs, p. 450


erythrocytic phase, p. 454


helminthiasis, p. 457


helminths, p. 457


prophylaxis, p. 454


tissue phase, p. 454


trichinosis, p. 457


virus, p. 448


image http://evolve.elsevier.com/KeeHayes/pharmacology/



Viruses


Viruses are more difficult to eradicate than most types of bacteria. A virus is an obligate intracellular organism that must reside within a living host cell to survive and reproduce. Viruses enter healthy cells and use their deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) to generate more viruses. The growth cycle of viruses depends on the host cell enzymes and cell substrates for viral replication. Viruses live and reproduce when they are within living cells. Examples of common viral infections include influenza, herpes virus infections, and viral hepatitis infections.


Viral Infections


Influenza, also called the flu, is a highly contagious viral infection that affects the nose, throat, and lungs. This virus is seasonal and more prevalent from fall to spring. Influenza has three antigen types: A, B, and C. Influenza A causes a moderate to severe infection. Influenza B usually causes mild illness in children. Influenza C is very rare in humans. This viral infection is transmitted easily via contaminated droplets during coughing, sneezing, or talking. Droplets enter into the respiratory tract of the unaffected person and begin replication 24 hours before the appearance of symptoms. Usually influenza has an abrupt onset with the first symptoms being high fever, headache, fatigue, and myalgia (muscle aches). A sore throat, nonproductive cough, watery nasal discharge, weakness, red watery eyes, chills, and photophobia may also occur.


Herpesviruses are large viruses that cause infections. Among the most familiar are herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2); varicella-zoster viruses (HSV-3 or VZV), more commonly known as chickenpox and shingles; Epstein-Barr virus (HSV-4 or EBV); and cytomegalovirus (HHV-5 or CMV). HSV-1 is usually associated with cold sores (vesicular lesions), which grow in neurons. The HSV-1 virus is capable of latency (ability to maintain disease potential without signs and symptoms). HSV-2 is usually associated with vesicular lesions and small ulcerations on the genitalia (genital herpes). The HSV-2 virus remains dormant by traveling through the peripheral nerves to the sacral dorsal root ganglia. The virus can be transported back the nerve root to the skin for reactivation at any time. While dormant, the virus continues to replicate. Both HSV-1 and HSV-2 are capable of causing recurrent infections. Both viruses can replicate in the mucous membranes and skin of the oropharynx or genitalia. The virus is transmitted by contact with infectious lesions or secretions. HSV-1 is spread by oral secretions from one individual to another. From the mouth, this virus can spread to the genital area by oral intercourse or poor hand washing. HSV-2 is usually spread by intimate sexual contact, or an infected mother can transmit the virus to her infant during childbirth. When signs and symptoms are present, they usually include eruption of small pustules and vesicles; fever; headache; malaise; myalgia; as well as tingling, itching, and pain in the genital area.


The varicella zoster virus (VZV or HSV-3) causes chickenpox and shingles. Chickenpox is a highly contagious viral infection that causes generalized pruritic vesicles and fever. It has become less common since a vaccine was developed; however, some outbreaks still occur. Shingles is a painful vesicular rash that can remain dormant in nerve cells. When a person who has previously been infected with chickenpox becomes older or develops a weakened immune system, the VZV can reactivate causing an outbreak along the region of skin innervated by the nerve where the virus resides. In addition to the rash, the patient may also develop fever, malaise, and myalgia.


Epstein-Barr virus (EBV or HSV-4) most commonly causes infectious mononucleosis, a condition manifested by fever, tonsillitis, and enlarged lymph nodes in the neck. EBV resides in lymphocytes, epithelial cells, and muscle cells and has a latency period.


Cytomegalovirus (CMV or HHV-5) is a very common infectious disease worldwide. It is thought that most adults have had this viral infection at one time and are unaware. Most individuals do not require treatment for CMV unless they are immunocompromised (e.g., babies or individuals who have had organ transplantations). CMV is transmitted via body fluids, especially saliva or urine; by kissing, sexual contact, or sharing food; or by a pregnant patient to the fetus. In susceptible individuals, CMV infection can lead to fatal pneumonia or blindness (due to an infected retina).


Hepatitis B (HBV) is a serious liver infection caused by the hepatitis B virus. The transmission of HBV is usually via a needlestick, intimate sexual contact, or childbirth. HBV is found in all body fluids, including blood, semen, and vaginal fluid. The signs and symptoms of HBV include anorexia, vomiting, diarrhea, jaundice, malaise, and myalgia.


A viral infection usually can be detected only after the virus has replicated itself. Viruses can cause mild to severe infections. General signs and symptoms of an acute viral infection include headache, low-grade fever (with a mild viral infection), nausea, vomiting, diarrhea, muscular pain, fatigue, and cough.


Vaccines


Vaccines are pharmacologic preparations that have been developed to provide immunity against and prevent diseases, such as smallpox, chickenpox, mumps, rabies, and influenza (see Chapter 36). The influenza virus vaccine may change annually because influenza (flu) virus changes its genetic structure each year. However, the influenza vaccine still promotes the production of antibodies by the immune system, despite the viruses’ varying genetic structures. After influenza vaccination (flu shot), most individuals develop high antibody titer levels providing protection against similar circulating viral strains. Eggs are used to produce the flu vaccine; therefore any allergies to eggs should be determined before flu vaccine is administered to the patient. The success rate of vaccine use to prevent influenza in healthy children and adults is 65% to 90%. In older adults, vaccines are effective 60% of the time, but less than 60% if an older adult has multiple health problems.


Diagnostic Tests for Influenza


Several office laboratory tests can be used to diagnose influenza. The diagnostic test Directigen Flu A has been available for many years to detect influenza A; however, it does not detect influenza B. Flu OIA, QuickVue Influenza Test, and ZstatFlu are diagnostic tests that identify both influenza A and B. These tests use throat swabs, nasal swabs, or nasal aspiration. Results are available within 10 to 20 minutes. QuickVue tends to be easy and fast for a rapid diagnosis of influenza A and B.


Antiviral Non-HIV Drugs


Antiviral drugs are used to prevent or delay the spread of a viral infection. They inhibit viral replication by interfering with viral nucleic acid synthesis in the cell. There are groups of antiviral drugs effective against various viruses, such as influenza A and B, herpes species, cytomegalovirus (CMV), and human immunodeficiency virus (HIV). Drugs for HIV are discussed in Chapter 35. The non-HIV antiviral drugs are listed in Table 33-1. Interferon alfa-2a and 2b are used to treat hepatitis B and C viruses (see Chapter 39).



TABLE 33-1


NON-HIV ANTIVIRALS































































































GENERIC (BRAND) ROUTE AND DOSAGE USES AND CONSIDERATIONS
Systemic Non-HIV Antivirals
Nonclassified Antivirals
amantadine HCl Influenza A:
A <65 y/C >9 y: PO: 200 mg/d in 1-2 divided doses
Older adults >65 y: 100 mg/d
C 1-8 y: PO: 5 mg/kg/d in 2 divided doses
Primary use is prophylaxis against influenza A. Well absorbed by GI tract. Pregnancy category: C; PB: UK; image: 11-15 h
cidofovir (Vistide) A: IV: 5 mg/kg in 100 mL NS over 60 minutes once/wk for 2 wk, then 3-5 mg/kg every other week. Take probenecid 2 g, 3 h before infusion, and take 1 g, 8 h after infusion. For CMV retinitis, especially in patients with AIDS. Kidney damage may occur; monitor kidney function. Pregnancy category: C; PB: UK; image: 17-65 h
foscarnet (Foscavir) CMV retinitis:
A: IV: 60 mg/kg infused over 1 h, q8h, for 2-3 wk or 90 mg/kg/d infused over 2 h, q12h
For herpesviruses (HSV-1 and HSV-2, VZV) and CMV retinitis. Can cause kidney damage and hyperphosphatemia. Closely monitor kidney function. Does not cause granulocytopenia or thrombocytopenia. Pregnancy category: C; PB: UK; image: 3-7 h
rimantadine HCl (Flumadine) A/C >10 y: PO: 100 mg b.i.d.
Older adults: PO: 100 mg/d
For prophylaxis and treatment against influenza A virus. Drug dose is usually reduced for patients with severe hepatic or renal impairment. Pregnancy category: C; PB: 40%; image: 13-65 h
Influenza virus vaccine (FLUCELVAX, Flublok) Flublok:
A : IM: 0.5 mL as single dose at beginning of influenza season
Flublok is for prophylaxis against influenza subtypes A and type B. Given IM only in deltoid muscle of upper arm at the beginning of influenza season. FLUCELVAX is for treatment of influenza subtypes A and B. Given IM only in deltoid muscle of upper arm. Pregnancy category: C; PB: UK; image: UK
telbivudine (Tyzeka) A: PO: 600 mg/d For chronic HBV. Pregnancy category: B; PB: 3.3%; image: 40-49 h.
adefovir dipivoxil (Hepsera) A/C >12 y: PO: 10 mg/d For chronic HBV. Pregnancy category: C; PB: <4%; image: 7.5 h.
entecavir (Baraclude) A: PO: 0.5-1 mg/d 2 h a.c. or p.c. For chronic HBV. Pregnancy category: C; PB: 13%; image: 128-149 h.
Purine Nucleosides
acyclovir (Zovirax) See Prototype Drug Chart 33-1.  
famciclovir (Famvir) Herpes zoster:
A: PO: 500 mg q8h × 7 d
Herpes simplex:
A: PO: 125 mg b.i.d. × 5 d or 1000 mg b.i.d. for 1 d
For herpes zoster and HSV-1. Pregnancy category: B; PB: <20%; image: 2-3 h
Varicella-zoster immune globulin (VariZIG) A/Adol >40 kg : IM: 625 international units/dose within 96 h of exposure
C 10-20 kg: 250 international units/dose IM within 96 h of exposure
For postexposure prophylaxis of varicella zoster. Pregnancy category: C; PB: UK; image: 22-30 d
ganciclovir sodium (Cytovene) A/C: IV: Initially: 5 mg/kg over 1 h q12h × 14-21 d; maint: 5 mg/kg/d over 1 h for 7 d, or 6 mg/kg/d over 1 h for 5 d For CMV systemic infection in immunocompromised patients. Pregnancy category: C; PB: 1%-2%; image: 2.5-6 h
ribavirin (Virazole) RSV:
C: Aerosol inhalation: 20 mg over 12-18 h/d for 3-7 d
Hepatitis C:
A >75 kg: PO: 600 mg b.i.d. for 24-48 wk
A <75 kg: PO: 400 mg in morning and 600 mg in evening
C: PO: 15 mg/kg/d
For respiratory syncytial viral infection in infants and children and for hepatitis C. Pregnancy category: X; PB: NA; image: 44 h
valacyclovir HCl (Valtrex) Herpes zoster:
A: PO: 1 g t.i.d. for 7 d
Recurrent genital herpes:
A: PO: 500 mg b.i.d. for 3 d
Effective against VZV causing herpes zoster (shingles) and recurrent genital herpes. Monitor kidney function. Encourage patient to increase water intake. GI disturbances and headaches are common side effects. Pregnancy category: B; PB: 14%-18%; image: 2.5-3.5 h
valganciclovir (Valcyte) A: PO: 900 mg b.i.d. with food for 21 d To treat CMV-infected cells of retinitis in AIDS patients. Inhibits viral DNA synthesis. May cause leukopenia, thrombocytopenia, bone marrow depression, and aplastic anemia. Pregnancy category: C; PB: 1%-2%; image: 18 h
Neuraminidase Inhibitors
oseltamivir phosphate (Tamiflu) A/C >40 kg: PO: 75 mg b.i.d. for 5d
C 23-40 kg: PO: 60 mg b.i.d. for 5d
C 15-23 kg: PO: 45 mg b.i.d. for 5d
C <15 kg: PO: 30 mg b.i.d. for 5d
For uncomplicated acute influenza A and B. Treatment should begin within 48 h of flu symptoms. May be taken with or without food. Side effects include transient nausea and vomiting. Pregnancy category: C; PB: 3%, image: 1-3 h
zanamivir (Relenza) A: inhaler: 2 oral inhalations (one 5-mg blister/inhalation) b.i.d. for 5 d For influenza A and B and H1N1 influenza. Treatment should begin within 48 h of flu symptoms. Less than 20% absorbed systemically. Pregnancy category: C; PB: <10%; image: 2.5-5 h
Topical Non-HIV Antivirals
penciclovir (Denavir) A: topical: Apply cream q2h during the day for 4 d For recurrent herpes labialis (cold sores).
Pregnancy category: B; PB: UK; image: UK
trifluridine (Viroptic) A: ophthalmic solution: 1 gt q2h during the day; max: 9 gtt/d Used primarily for keratoconjunctivitis due to herpes simplex virus. Pregnancy category: C; PB: UK; image: 12 min


Image


A, Adult; a.c., before meals; AIDS, acquired immunodeficiency syndrome; b.i.d., twice a day; C, child; CMV, cytomegalovirus; d, day; DNA, deoxyribonucleic acid; GI, gastrointestinal; gt, drop; gtt, drops; h, hour; HIV, human immunodeficiency virus; HSV, herpes simplex virus; IV, intravenous; maint, maintenance; max, maximum; PB, protein-binding; p.c. after meals; PO, by mouth; image, half-life; t.i.d., three times a day; UK, unknown; VZV, varicella-zoster virus; wk, week; y, year; >, greater than; <, less than.


Nonclassified Antivirals


The first two related antivirals, amantidine hydrochloride and rimantadine hydrochloride (Flumadine), were used to treat type A influenza. Both these antivirals are nonclassified antivirals. Originally, amantidine was used to treat parkinsonism and only later was found to be effective against influenza A. Neither amantidine nor rimantadine are effective against type B influenza. Three other nonclassified antivirals are (1) cidofovir, which is used to treat CMV retinitis; (2) foscarnet (Foscavir), which is used to treat HIV retinitis and herpes simplex infection in patients with acquired immunodeficiency syndrome (AIDS) (immune disorder characterized by opportunistic diseases); and (3) vidarabine (Vira-A), which is used to treat herpesvirus. In the late 1990s, the U.S. Food and Drug Administration (FDA) approved zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), two drugs that inhibit the replication and spread of the influenza virus if given within 48 hours of symptoms; thus, early diagnosis of influenza is important.


Side Effects and Adverse Reactions


The side effects and adverse reactions to amantadine include central nervous system (CNS) effects, such as insomnia, depression, anxiety, confusion, and ataxia; orthostatic hypotension; neurologic problems, such as weakness, dizziness, and slurred speech; and gastrointestinal (GI) disturbances, such as anorexia, nausea, vomiting, and diarrhea. The CNS side effects of rimantadine occur less often than with amantadine.


Topical Antivirals


There are three topical antiviral drugs: idoxuridine (Herplex Liquifilm), penciclovir (Denavir), and trifluridine (Viroptic). These topical agents are used to treat herpes simplex viruses.


Neuraminidase Inhibitors


Neuraminidase inhibitors are a group of drugs that decrease the release of the virus from infected cells, thus decreasing viral spread and shortening the duration of flu symptoms. Zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) are two neuraminidase inhibitors that should be taken within 48 hours of flu symptoms. These drugs inhibit the activity of neuraminidase, a viral glycoprotein, and are effective against type A and B influenza viruses. Zanamivir and oseltamivir phosphate are not substitutes for the “flu shot.”


Gamma Globulin (Immune Globulin)


Gamma globulin (IgG) is rich in antibodies found in the blood. It provides a passive form of immunity to a virus by blocking the penetration of the virus into the host cell. It is administered during the early infectious stage of an illness to prevent a viral invasion in the body.


Human immune globulin (Gamastan) is administered intramuscularly (IM). A single-dose injection protects for approximately 2 to 3 weeks; it may be repeated 2 to 3 weeks following the first dose. For patients who need an immediate increase in immune globulin levels, intravenous (IV) immune globulin (Gamimune N) may be administered.


Purine Nucleosides


The synthetic purine nucleoside antiviral group is effective in interfering with the steps of viral nucleic acid (DNA) synthesis. Drugs in this group of nucleoside analogs include ribavirin (Virazole), acyclovir (Zovirax), famciclovir (Famvir), ganciclovir sodium (Cytovene), and valacyclovir (Valtrex). These drugs are effective in combating herpes simplex viruses (HSV-1, HSV-2), herpes zoster (shingles), varicella-zoster virus (chickenpox), and CMV. Valganciclovir (Valcyte) is a prodrug of ganciclovir and is effective for treating CMV retinitis in patients with AIDS.


The antiviral drug ribavirin was first marketed in 1986. It is used to treat respiratory syncytial virus (RSV) in children and respiratory infections caused by the influenza A and B viruses in older adults. Ribavirin is administered by aerosol.


Acyclovir


Acyclovir was introduced as an antineoplastic drug and later was found to be effective against herpesvirus, especially HSV-2, but also against HSV-1, herpes zoster (shingles), and CMV (which can cause congenital defects). There has been reported resistance to acyclovir as a result of the lack of viral-producing enzyme (thymidine kinase) needed to convert the drug to an effective antiviral compound. Prototype Drug Chart 33-1 lists the drug data for acyclovir sodium.



image Prototype Drug Chart 33-1


Acyclovir Sodium



































Drug Class Dosage
Antiviral
Trade Name: Zovirax
Pregnancy Category: B
Herpes simplex virus:
A: PO: 400 mg t.i.d. for 5-10 d
A: IV: 5 mg/kg q8h for 10-21 d
Herpes zoster virus:
A: PO: 800 mg q4h 5 ×/d for 7-10 d
Herpes simplex encephalitis:
A: IV: 10 mg/kg q8h for 10 d
Contraindications Drug-Lab-Food Interactions
Hypersensitivity, severe renal or hepatic disease
Caution: Electrolyte imbalance, dehydration, seizure disorder, nursing mothers, young children
Drug: Increase nephro-neurotoxicity with aminoglycosides, probenecid, interferon; decreases effect of phenytoin
Lab: May increase AST, ALT, BUN
Pharmacokinetics Pharmacodynamics
Absorption: PO: Slowly absorbed
Distribution: PB: 10%-30%
Metabolism: image: PO: 2.5-3 h
Excretion: Urine and breast milk
PO: Onset: UK
Peak: 1.5-2 h
Duration: 4-8 h
IV: Onset: Rapid
Peak: 1-2 h
Duration: 4-8 h
Therapeutic Effects/Uses
To treat HSV-1, HSV-2 (genital)
Mode of Action: Interference with viral synthesis of DNA
Side Effects Adverse Reactions
Nausea, anorexia, vomiting, diarrhea, headache, tremors, agitation, lethargy, rash, pruritus, increased bleeding time, phlebitis at IV site Urticaria, anemia, crystalluria, paresthesias
Life-threatening: Neuropathy, seizures, nephrotoxicity (large doses), thrombocytopenia, leukopenia,

Stay updated, free articles. Join our Telegram channel

Oct 8, 2016 | Posted by in NURSING | Comments Off on Antivirals, Antimalarials, and Anthelmintics

Full access? Get Clinical Tree

Get Clinical Tree app for offline access